@article {7606,
	title = {Developments in the treatment of locally advanced cervical cancer},
	journal = {Forum of Clinical Oncology},
	volume = {4},
	year = {2013},
	note = {Export Date: 21 February 2017},
	month = {2013},
	pages = {32 - 43},
	abstract = {Despite the available prevention and early detection strategies, squamous-cell carcinoma of the uterine cervix is still diagnosed as locally advanced disease in a large proportion of patients. Treatment with cisplatin, in combination with external beam irradiation, has been the cornerstone of treatment in this setting for more than two decades. Induction chemotherapy strategies followed by concurrent chemo-radiation or surgery and pre-operative concurrent chemo-radiation have been recently implemented in clinical trials in an effort to optimize both local control and the occurrence of distant metastases. More recently, combinations of chemotherapy or radiotherapy with molecular agents targeting critical pathways in cervical malignant transformation are being assessed in clinical trials. In this paper, we review the role of cisplatin in the disease in the context of other potent radiosensitizers. We also discuss all recently implemented therapeutic modalities for the treatment of locally advanced cervical cancer with emphasis on the novel induction strategies. Concerns regarding treatment-related toxicity in the context of co-morbidities and the need for potent predictive biomarkers for individualized therapeutic approach are also addressed.},
	keywords = {Cervical cancer, Chemotherapy, Locally advanced, Prognostic and predictive markers, Radiotherapy, Toxicity},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84877153440\&partnerID=40\&md5=78d7cc6a0ad8fb2e6a29ae1f2d9cc1cd},
	author = {Mountzios, G. and Pectasides, D. and Pectasides, E. and Dimopoulos, M.-A. and Papadimitriou, C.A.}
}
